Kevin Mcnamara Sells 2,000 Shares of Chemed (NYSE:CHE) Stock

Chemed Corporation (NYSE:CHE) CEO Kevin Mcnamara sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $437.55, for a total transaction of $875,100.00. Following the sale, the chief executive officer directly owned 94,197 shares of the company’s stock, valued at $41,215,897.35. The trade was a 2.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Chemed Price Performance

Shares of NYSE:CHE traded up $4.43 during trading on Tuesday, reaching $440.86. 95,587 shares of the company’s stock traded hands, compared to its average volume of 152,777. The stock has a market capitalization of $6.24 billion, a P/E ratio of 23.31, a price-to-earnings-growth ratio of 2.69 and a beta of 0.43. Chemed Corporation has a 12 month low of $408.42 and a 12 month high of $623.60. The company has a 50 day moving average of $441.60 and a 200-day moving average of $476.92.

Chemed (NYSE:CHE) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). Chemed had a return on equity of 25.89% and a net margin of 11.02%.The company had revenue of $624.90 million for the quarter, compared to analyst estimates of $626.04 million. During the same quarter in the previous year, the company posted $5.64 earnings per share. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. Equities research analysts predict that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Chemed Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Monday, November 17th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Monday, November 17th. Chemed’s dividend payout ratio is currently 12.69%.

Institutional Investors Weigh In On Chemed

Institutional investors have recently modified their holdings of the stock. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Chemed in the 1st quarter worth about $4,670,000. Avantax Advisory Services Inc. lifted its stake in Chemed by 6.5% in the first quarter. Avantax Advisory Services Inc. now owns 1,442 shares of the company’s stock valued at $887,000 after acquiring an additional 88 shares during the last quarter. Cetera Investment Advisers lifted its position in shares of Chemed by 6.2% in the first quarter. Cetera Investment Advisers now owns 1,715 shares of the company’s stock worth $1,056,000 after buying an additional 100 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Chemed by 4.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,550 shares of the company’s stock worth $2,184,000 after buying an additional 144 shares during the last quarter. Finally, Inspire Advisors LLC bought a new stake in Chemed in the 1st quarter valued at $221,000. Institutional investors and hedge funds own 95.85% of the company’s stock.

Analysts Set New Price Targets

CHE has been the subject of a number of research analyst reports. Oppenheimer reduced their price target on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a research note on Thursday, July 31st. Bank of America decreased their target price on Chemed from $610.00 to $595.00 and set a “buy” rating for the company in a research note on Wednesday, September 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Chemed in a research report on Wednesday, October 8th. Jefferies Financial Group upgraded shares of Chemed from a “hold” rating to a “buy” rating and raised their price objective for the company from $490.00 to $550.00 in a research report on Tuesday, September 2nd. Finally, Royal Bank Of Canada dropped their target price on shares of Chemed from $589.00 to $572.00 and set an “outperform” rating on the stock in a report on Monday, November 10th. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Chemed currently has a consensus rating of “Moderate Buy” and a consensus target price of $574.25.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.